Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | CCNC | P24863 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 4/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | TTK | P33981 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24301059 | 0.90 | CCNC (0.49) | EGFRCCNCCDK8TNK2MET | |
| SCHEMBL29528376 | 0.90 | CCNC (0.49) | EGFRCCNCCDK8TNK2MET | |
| SCHEMBL30919511 | 0.89 | FGFR3 (0.45) | EGFRCCNCCDK8TNK2MET | |
| SCHEMBL28657129 | 0.80 | DDB1 (0.57) | CCNCCDK8TNK2METDDB1 | |
| SCHEMBL30926322 | 0.79 | CDK1 (0.47) | EGFRMETFGFR1FGFR2FGFR3 | |
| SCHEMBL29249379 | 0.79 | DDB1 (0.56) | CCNCCDK8TNK2METDDB1 | |
| SCHEMBL28856090 | 0.79 | CCNC (0.49) | EGFRCCNCCDK8TNK2MET | |
| SCHEMBL31333791 | 0.79 | CDK1 (0.47) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL30725475 | 0.78 | STK17B (0.42) | EGFRTTKCDK1CCNB1CCNE1 | |
| SCHEMBL25329417 | 0.78 | STK17B (0.42) | EGFRTTKCDK1CCNB1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618755-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2024107746-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024107746-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES (US) | 2024-05-23 | — | — | WO | disclosed |
| US-10435400-B2 | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) | 2019-10-08 | — | — | US | disclosed |
| US-20170008889-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) | 2017-01-12 | — | — | US | disclosed |
| US-20170008889-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) | 2017-01-12 | — | — | US | disclosed |
| EP-3112364-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127872-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | 上海海雁医药科技有限公司 | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008889-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | ERBB2, EGFR, ERBB3 | EGFR 2/4885CCNC 3215/4885CDK8 767/4885 |
| US-10435400-B2 | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | ERBB2, EGFR, ERBB3 | EGFR 2/4885CCNC 3215/4885CDK8 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.